Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574114 | 0.80 | TSHR (0.42) | TSHRSMN1; SMN2MAPTKMT2ARAB9A | |
| SCHEMBL7599922 | 0.77 | LMNA (0.39) | TSHRSMN1; SMN2MAPTKMT2AALDH1A1 | |
| SCHEMBL236402 | 0.76 | ALDH1A1 (0.50) | TSHRSMN1; SMN2MAPTKMT2ARAB9A | |
| SCHEMBL10818200 | 0.76 | TSHR (0.46) | TSHRSMN1; SMN2MAPTKMT2ARAB9A | |
| SCHEMBL11232663 | 0.74 | SMN1; SMN2 (0.37) | TSHRSMN1; SMN2MAPTKMT2ARAB9A | |
| SCHEMBL7627412 | 0.73 | L3MBTL1 (0.32) | LMNA | |
| SCHEMBL12319214 | 0.73 | SMN1; SMN2 (0.43) | TSHRSMN1; SMN2MAPTKMT2ARAB9A | |
| SCHEMBL7627409 | 0.73 | L3MBTL1 (0.32) | LMNA | |
| SCHEMBL2408985 | 0.73 | SMN1; SMN2 (0.43) | TSHRSMN1; SMN2MAPTKMT2ARAB9A | |
| SCHEMBL363871 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6639032-B2 | Simple, environmentally friendly copolymerization of allyl monomers | EASTMAN KODAK COMPANY | 2003-10-28 | — | — | US | claimed |
| US-20030158357-A1 | Highly branched polymer from telomerization | EASTMAN KODAK COMPANY | 2003-08-21 | — | — | US | claimed |
| CN-113816855-B | Method for synthesizing chiral allyl carboxylic ester | 常州大学 | 2022-09-27 | — | — | CN | disclosed |
| CN-113816855-A | Method for synthesizing chiral allyl carboxylic ester | 常州大学 | 2021-12-21 | — | — | CN | disclosed |
| US-20150321983-A1 | A PROCESS FOR THE PREPARATION OF OSPEMIFENE | FERMION OY (FI) | 2015-11-12 | — | — | US | disclosed |
| EP-2909163-A1 | A PROCESS FOR THE PREPARATION OF OSPEMIFENE | Fermion Oy (FI) | 2015-08-26 | — | — | EP | disclosed |
| WO-2014060640-A1 | A PROCESS FOR THE PREPARATION OF OSPEMIFENE | FERMION OY (FI) | 2014-04-24 | — | — | WO | disclosed |
| US-20130035479-A1 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM PHARMA (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20100168054-A1 | Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation | OM PHARMA (CH) | 2010-07-01 | — | — | US | disclosed |
| EP-2106403-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM Pharma (CH) | 2009-10-07 | — | — | EP | disclosed |
| WO-2008059307-A2 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | OM PHARMA (CH) | 2008-05-22 | — | — | WO | disclosed |
| CN-1139925-A | 'Delta' 12,13-iso-taxol analogs, antineoplastic use and pharmaceutical compositions containing them | UPJOHN CO (US) | 1997-01-08 | — | — | CN | disclosed |
| US-5565560-A | TREATING AUTOIMMUNE DISEASES, PREVENTING TRANSPLANT REJECTION | MERCK & CO., INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0724570-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-08-07 | — | — | EP | disclosed |
| EP-0722448-A1 | O-ARYL, O-ALKYL, O-ALKENYL AND O-ALKYNYL-MACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO. INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5532248-A | O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity | MERCK CO., INC. (US) | 1996-07-02 | — | — | US | disclosed |
| WO-1995034568-A1 | ARYL, ALKYL, ALKENYL, AND ALKYNYLMACROLIDES | MERCK & CO., INC. (US) | 1995-12-21 | — | — | WO | disclosed |
| WO-1995011231-A1 | AMIDINO DERIVATIVES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | G. D. SEARLE & CO. (US) | 1995-04-27 | — | — | WO | disclosed |
| WO-1995009857-A1 | O-ARYL, O-ALKYL, O-ALKENYL AND O-ALKYNYL-MACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO., INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0441218-A2 | Anthracycline-glycosyl prodrugs, process for their preparation and their use in combination with functionalised tumour-specific enzyme conjugates | BEHRINGWERKE Aktiengesellschaft (DE) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150321983-A1 | A PROCESS FOR THE PREPARATION OF OSPEMIFENE | CYP2F1, OGFR, OPRM1 | TSHR 1266/4885SMN1; SMN2 859/4885MAPT 1435/4885 |
| US-20130035479-A1 | FUNCTIONALIZED BETA 1,6 GLUCOSAMINE DISACCHARIDES AND PROCESS FOR THEIR PREPARATION | FUT6, FUT5, B3GNT2 | TSHR 3844/4885SMN1; SMN2 3818/4885MAPT 4267/4885 |
| US-20100168054-A1 | Functionalized Beta 1,6 Glucosamine Disaccharides and Process for Their Preparation | FUT6, FUT5, B3GNT2 | TSHR 3844/4885SMN1; SMN2 3818/4885MAPT 4267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.